Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710032 | 1.00 | GRIK1 (0.36) | GRIK1BACE1LMNAMAPTGRM5 | |
| SCHEMBL6713722 | 0.92 | NR2E1 (0.35) | GRIK1BACE1LMNAMAPTGRM5 | |
| SCHEMBL6708711 | 0.91 | IRAK4 (0.38) | GRIK1LMNAMAPTGRM5PPARG | |
| SCHEMBL6708708 | 0.91 | IRAK4 (0.38) | GRIK1LMNAMAPTGRM5PPARG | |
| SCHEMBL6707654 | 0.89 | ALK (0.40) | LMNAMAPTMAP2K1PPARGABL1 | |
| SCHEMBL6707657 | 0.89 | ALK (0.40) | LMNAMAPTMAP2K1PPARGABL1 | |
| SCHEMBL6709918 | 0.88 | GRIK1 (0.38) | GRIK1BACE1LMNAMAPTGRM5 | |
| SCHEMBL6712425 | 0.87 | TP53 (0.38) | GRIK1LMNAMAPTGRM5 | |
| SCHEMBL6708956 | 0.87 | LRRK2 (0.38) | GRIK1BACE1LMNAMAPT | |
| SCHEMBL6710021 | 0.86 | GRIK1 (0.39) | GRIK1BACE1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GRIK1 3885/4885BACE1 3406/4885LMNA 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.